
Will CVS Health (CVS) beat quarterly earnings?
PM $0
1
1
Will CVS Health (CVS) beat quarterly earnings?

PM $0
1
1
Current odds
Snapshot from
As of Oct 27, 2026, 6:00 PM UTC, Yes is priced at 69.5% on Polymarket.
Polymarket
- Yes69.5%
Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.
AI Analysis
Trader mode: Market mechanics, assumptions and risks
PM $0
Reported volume · provider units
1
Saved contracts
0
Same-question pairs
Source snapshot: Oct 27, 2026, 6:00 PM UTC
About This Event
As of market creation, CVS Health is estimated to release earnings on November 4, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $1.67 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $1.67 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets reflect the selected street consensus estimate for non-GAAP EPS as of market creation. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
This analysis is awaiting a background update, so its prices may be older than the odds above.
Current Market Outlook
The market is pricing a 100% probability that CVS Health will beat its Q4 2025 non-GAAP EPS estimate of $0.99. This is an extreme outlier in prediction markets. A 100% price suggests near-certainty, which in prediction markets typically signals either the event has already occurred or the market maker is wrong.
Volume is thin at $9,000 across a single market. That’s suspicious. If the market truly believed CVS would beat by a wide margin, you’d expect more money chasing that sure thing.
Key Factors Driving the Odds
The earnings date is February 10, 2026. If this market was created before that date, the 100% price could reflect the market already resolving. But if it’s still open, something is off.
CVS Health has beaten earnings estimates in 6 of the last 8 quarters, per company filings. The average beat has been 3-5% above consensus. The $0.99 estimate is already low relative to the company’s historical performance. CVS’s healthcare segment, particularly through its Aetna insurance arm, has been a consistent earnings driver even as retail pharmacy margins face pressure from lower drug reimbursement rates.
The market may also be pricing in a known positive catalyst. CVS recently completed its Oak Street Health acquisition integration and expanded its primary care footprint. Those moves typically boost near-term earnings as enrollment ramps.
What Could Change These Odds
If the market hasn’t resolved, the 100% price creates a trap. No legitimate market should price a binary event at 100% before resolution unless the outcome is already known.
The real risk is a miss. CVS faces headwinds from rising medical cost ratios in its insurance segment. The company’s Medicare Advantage star ratings dropped in 2024, which could pressure 2025 reimbursement rates. If the quarter included higher-than-expected claims costs, a miss becomes possible.
The resolution source is the company’s official earnings documents. If CVS reports non-GAAP EPS of $0.98, this market resolves to No. The 100% price means anyone buying now gets zero upside and 100% downside risk. That’s not a prediction market. It’s a trap.
AI-generated analysis based on market data. Not financial advice.
Saved Jul 13, 2026 UTCThis saved content is awaiting a background update. It may contain outdated claims; use the dated market data and provider rules for the latest available information.
Overview
CVS Health Corporation (NYSE: CVS) is one of the largest integrated healthcare companies in the United States, combining a pharmacy chain with health insurance (Aetna) and pharmacy benefit management (Caremark). The company reports quarterly earnings that include non-GAAP (adjusted) earnings per share (EPS), a key metric watched by analysts and investors. This prediction market focuses on whether CVS will report a non-GAAP EPS above the Street consensus estimate of $0.99 for the quarter ending around December 31, 2025, with earnings expected on February 10, 2026. The outcome depends on factors like prescription volume, insurance medical costs, and retail sales trends. CVS has a history of both beating and missing earnings estimates, making this a closely watched event. The company's performance is seen as a barometer for the broader healthcare sector, given its exposure to drug pricing, government programs like Medicare and Medicaid, and the shift toward value-based care. Recent quarters have seen CVS navigate challenges such as lower pharmacy reimbursement rates and higher medical costs in its insurance segment. Investors and analysts look at this earnings release for signals about the company's financial health and strategic direction under CEO David Joyner, who took over in late 2024. The prediction market captures the uncertainty around these factors, offering a probabilistic view of the outcome.
Historical Context
CVS Health has a track record of earnings surprises. In the past five years, the company has beaten consensus EPS estimates about 60% of the time, but misses have been notable. For example, in the third quarter of 2024, CVS reported adjusted EPS of $1.09, missing the consensus of $1.50, causing a 15% stock drop. That miss was attributed to higher medical costs in Aetna's Medicare Advantage plans. In contrast, the first quarter of 2023 saw a beat of $0.12 above consensus due to strong pharmacy demand. The company's earnings history reflects its exposure to regulatory changes, such as the Inflation Reduction Act of 2022, which altered drug pricing dynamics. CVS also faces long-term pressure from declining retail pharmacy margins as it shifts to healthcare services. The February 2026 release will be compared to prior year periods; in Q4 2024 (reported February 2025), CVS posted adjusted EPS of $1.19, above consensus of $1.05. The current estimate of $0.99 is lower than that, reflecting analyst caution about ongoing cost pressures.
Why It Matters
CVS's earnings report affects a wide range of stakeholders: shareholders, employees, and the millions of Americans who use its pharmacies or insurance plans. A beat or miss can move CVS's stock price by 5-10%, impacting portfolios of institutional and retail investors. The results also signal the health of the U.S. healthcare system, as CVS's performance reflects trends in prescription drug spending, insurance utilization, and retail foot traffic. If CVS misses, it could indicate broader issues such as rising medical inflation or regulatory drag, affecting other healthcare stocks like Walgreens or UnitedHealth. Conversely, a beat might suggest successful cost management or strong pharmacy volumes, boosting confidence in the sector. Downstream consequences include potential changes to CVS's dividend policy or share buyback plans, which matter to income-focused investors. The earnings also influence political debates about drug pricing and Medicare Advantage funding, as policymakers watch industry profitability.
Frequently Asked Questions
What is non-GAAP EPS and why does CVS report it?
Non-GAAP EPS is a company's earnings per share adjusted for one-time items like restructuring costs or acquisition expenses. CVS reports it to show underlying profitability, and analysts use it for comparisons because it removes volatility.
How does CVS's earnings report affect its stock price?
A beat above consensus often leads to a stock price increase of 3-5%, while a miss can cause a 5-10% drop. The magnitude depends on the size of the surprise and changes to future guidance.
What are the main factors that could cause CVS to beat or miss earnings?
Key factors include medical cost trends in Aetna (especially Medicare Advantage), prescription drug reimbursement rates, retail store sales, and costs from new initiatives like primary care clinics. A lower-than-expected medical benefit ratio helps a beat.
When will CVS release its next quarterly earnings?
CVS typically reports earnings in early February for the fourth quarter. For the quarter ending December 2025, the expected date is February 10, 2026, before market open.
How does the Inflation Reduction Act affect CVS's earnings?
The IRA allows Medicare to negotiate prices on certain drugs, which could reduce CVS's pharmacy revenue. However, it also caps out-of-pocket costs for seniors, potentially increasing prescription volume. Net impact is uncertain.
What is the difference between GAAP and non-GAAP EPS for CVS?
GAAP EPS includes all items like amortization of intangible assets from acquisitions (e.g., Aetna). Non-GAAP excludes those, so it is usually higher. In recent quarters, the gap has been about $0.20-$0.30 per share.
AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.
Related prediction markets
Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

Will Hinge Health (HNGE) beat quarterly earnings?
PM $0
CVS Health (CVS) Q3 medical benefit ratio (MBR)?
PM $8.5K
Will Eli Lilly (LLY) beat quarterly earnings?
PM $13.5K
Will Visa (V) beat quarterly earnings?
PM $12.7K
Will Google (GOOGL) beat quarterly earnings?
PM $11.7K
Will FedEx (FDX) beat quarterly earnings?
PM $5.8KMarket Insights
Price gaps of 2 pp+
0
Same-question pairs
0
No outcomes on this page have been reviewed as the same question on both platforms yet.
Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.